PDS Biotechnology Corp (PDSB)

[Fress]

SARS-CoV-2-specific T cells are key players in decreasing COVID-19 mortality
The role of SARS-CoV-2-specific T cells.
T cells as 'the most valuable players
https://www.news-medical.net/news/20210131/SARS-CoV-2-specific-T-cells-are-key-players-in-decreasing-COVID-19-mortality.aspx

Dangerous new strains may incubate in sickest...
https://news.yahoo.com/dangerous-coronavirus-strains-may-incubate-192505798.html

Biden health adviser warns of variants, future lockdowns...
https://www.msn.com/en-us/money/markets/biden-health-adviser-warns-of-virus-variants-future-lockdowns/ar-BB1dgjTD?ocid=uxbndlbing

RED ALERT Brazilian Government accused of deliberately allowing coronavirus to spread as death toll hits 222,000
Authorities were "intentionally" trying to infect the public with Covid, a study by a top university has claimed.
https://www.thesun.co.uk/news/13896814/brazilian-government-coronavirus-deaths/


Israel extends lockdown, sees delay in covid turnaround...
https://news.trust.org/item/20210131211623-nidpj


Thousands break rules for funeral...
https://www.jpost.com/breaking-news/brisk-yeshiva-head-rabbi-meshulam-dovid-soloveitchik-passes-away-at-99-657288
--------------------------------------------------------------------
Development of PDS0203 - A second generation COVID-19 vaccine that
promotes powerful T-cell responses and neutralizing antibodies.

clinical studies show powerful induction of long-lasting polyfunctional CD8+ and
CD4+ anti-SARS-CoV-2 T-cells.

PDS generated data shows induction of
SARS-CoV-2 specific CD8+ T-cells with
Versamune®2

Mt. Sinai data shows Versamune® promotes
induction of neutralizing antibodies with
lowest doses of SARS-CoV-2 antigen1

As previously disclosed, PDS Biotech has generated robust clinical data demonstrating that PDS0203 CV-19 elicits a 30-45 fold increase in the induction of highly active and potent virus-specific T-cells within 14 days of treatment compared to the vaccine without Versamune®. Importantly, the study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for longer term protection. The vaccine has also demonstrated strong and long-lasting induction of neutralizing antibodies. The PDS0203 subunit vaccine is based on recombinant proteins and does not require the use of inactivated viruses, traditional adjuvants, DNA or RNA to induce robust protective immune responses.


T cells can mount attacks against many SARS-CoV-2 targets -- even on new virus variant. New research gives detailed look at vulnerable sites on the novel coronavirus -- beyond the receptor binding domain.


PDSB Versamune® possesses the key characteristics of a safe and effective immunotherapeutic treatment.


PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency.

“We are excited to continue advancing the partnership with PDS Biotech, and we are thrilled to have the support of ANVISA to provide the opportunity to develop a treatment in Brazil in the fight against this pandemic.”


PDSB the data for the oncology and CV-19 data is remarkable.

Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose.

Tumor Regression: (76%)

PDSB Three Phase 2 oncology trials with the top cancer institutions & Merck.

PDSB is partnered with the three top cancer institutes in the world. And Merck one of the biggest biotech companies in the world.

1)The University of Texas MD Anderson Cancer Center (colloquially MD Anderson Cancer Center) is a comprehensive cancer center in Houston, Texas. It is the largest cancer center in the US and one of the original three comprehensive cancer centers in the country.
https://www.mdanderson.org/


2)The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. Our team of approximately 3,500 is part of the National Institutes of Health (NIH), one of 11 agencies that make up the Department of Health and Human Services (HHS)
https://www.cancer.gov/about-nci


3)The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services.
https://www.niaid.nih.gov/

PDSB VERSAMUNE®
PLATFORM
Our Versamune® platform trains the immune system to unleash a powerful targeted T-cell attack and could dramatically improve treatment and patient outcomes across the cancer spectrum.


Multiple Peer Reviewed papers:

1.Journal for Immuno Therapy of Cancer:
https://jitc.bmj.com/content/8/1/e000612

2.the Journal of Immunology:
https://www.jimmunol.org/content/202/12/3524

PDSB White Paper:
https://pdsbiotech.com/images/pdf/presentation/2021/Whitepaper-2021_v6.pdf




Versamune® has demonstrated immunological compatibility with a
wide array of tumor and pathogenic antigens.

• Today, 4 tumor antigens are being utilized with the Versamune® platform,
more than 75 tumor antigens have been identified.
• We are currently progressing two Versamune®-based infectious disease.
vaccines, one for SARS-COVID-19, and one for universal influenza
• Versamune®’s unique flexibility means it may work well with a wide range of identified tumor and pathogenic antigens
• Potential to continuously expand development of Versamune®-based products through partnerships and licensing.

PDSB DEBT FREE 22 million shares 45% held now by institutions & insiders.

PDSB only a 72 million market cap today. And funded through mid 2022.

PDSB $10.00 = 220 million market cap

PDSB $20.00 = 440 million market cap

PDSB $100.00= 2.2 billion market cap.

put your shares Good till Cancelled GTC sky high shares are very scarce.

PDSB website:
https://www.pdsbiotech.com/

PDSB 2021 Biz presentation:
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Jan_2021_FINAL-1.pdf

Oppenheimer gave an over weight buy target at $7.00 last month.


Chardan Capital Reiterated Rating Buy $10.00


Alliance Global Partners Boost Price Target Buy $6.50


Noble Financial Reiterated Rating Buy $6.60


HC Wainwright Upgrade from Neutral to Buy $6.00


JNJ states that T-Cell are key in COVID Vaccine - $PDSB is w T-Cell platform.

Normalcy will return only with second generation of Covid-19 vaccine: Bill Gates.


$PDSB